Telavancin

Telavancin is a topic covered in the Washington Manual of Medical Therapeutics.

To view the entire topic, please or .

The Washington Manual of Medical Therapeutics helps you diagnose and treat hundreds of medical conditions. Consult clinical recommendations from a resource that has been trusted on the wards for 50+ years. Explore these free sample topics:

-- The first section of this topic is shown below --

General Principles

Telavancin (7.5–10 mg/kg q24–48h, based on CrCl) is a lipoglycopeptide antibiotic that is FDA approved for treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by S. aureus and for complicated skin and skin structure infections. Telavancin is broadly active against gram-positive bacteria, including MRSA, VISA, heteroresistant VISA (hVISA), daptomycin- and linezolid-resistant S. aureus, streptococci, vancomycin-sensitive enterococci, and some gram-positive anaerobes. The agent is not active against gram-negative bacteria, vancomycin-resistant S. aureus, and VRE.

-- To view the remaining sections of this topic, please or --

General Principles

Telavancin (7.5–10 mg/kg q24–48h, based on CrCl) is a lipoglycopeptide antibiotic that is FDA approved for treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by S. aureus and for complicated skin and skin structure infections. Telavancin is broadly active against gram-positive bacteria, including MRSA, VISA, heteroresistant VISA (hVISA), daptomycin- and linezolid-resistant S. aureus, streptococci, vancomycin-sensitive enterococci, and some gram-positive anaerobes. The agent is not active against gram-negative bacteria, vancomycin-resistant S. aureus, and VRE.

There's more to see -- the rest of this entry is available only to subscribers.